Magdalena Vikdahl1, Maine Carlsson2, Jan Linder3, Lars Forsgren3, Lena Håglin4. 1. Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, SE-901 87 Umeå, Sweden. Electronic address: magdalena.vikdahl@gmail.com. 2. Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, SE-901 87 Umeå, Sweden. 3. Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 87 Umeå, Sweden. 4. Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, SE-901 87 Umeå, Sweden.
Abstract
BACKGROUND & AIMS: Weight loss is strongly associated with Parkinson's disease (PD) and impacts symptoms and disease progression. The aim of this study was to describe changes in body composition and to explore how body weight (BW), relates to disease progression and medication in the early phase of PD. METHODS: Participants in a prospective community-based case-control study of PD were followed-up three years after initial diagnosis. Anthropometric and bioelectrical impedance spectroscopy (BIS) measurements were used together with Mini Nutritional Assessment (MNA), a 24-h recall (24-HR) and a 3-day food registration (3-DFR) to complete the evaluation of nutritional status. Disease severity was assessed using the Mini Mental State Examination (MMSE), the Unified Parkinson's Disease Rating Scale motor score (UPDRS III), and the Hoehn and Yahr rating. RESULTS: The PD patients' BW gained 1.62 kg (±4.60, P = 0.009), an increase that significantly correlated with fat mass (FM) (r = 0.74), waist size (r = 0.65), waist/height ratio (r = 0.64), and total skin fold (r = 0.77). Linear regression showed an association between change in BW and physical activity level (PAL) (B = -8.554; P = 0.025) confirmed by the multiple linear regression. Linear regression also revealed an association between change in FM and MMSE (B = 0.654; P = 0.027). CONCLUSION: In early PD, weight gain was revealed over three years accompanied by an increase in FM and waist circumference. An inverse relation was revealed between change in BW and PAL. The MMSE, UPDRS III, and Hoehn and Yahr rating were unchanged. Medication and swallowing difficulties were not associated with change in BW.
BACKGROUND & AIMS:Weight loss is strongly associated with Parkinson's disease (PD) and impacts symptoms and disease progression. The aim of this study was to describe changes in body composition and to explore how body weight (BW), relates to disease progression and medication in the early phase of PD. METHODS:Participants in a prospective community-based case-control study of PD were followed-up three years after initial diagnosis. Anthropometric and bioelectrical impedance spectroscopy (BIS) measurements were used together with Mini Nutritional Assessment (MNA), a 24-h recall (24-HR) and a 3-day food registration (3-DFR) to complete the evaluation of nutritional status. Disease severity was assessed using the Mini Mental State Examination (MMSE), the Unified Parkinson's Disease Rating Scale motor score (UPDRS III), and the Hoehn and Yahr rating. RESULTS: The PDpatients' BW gained 1.62 kg (±4.60, P = 0.009), an increase that significantly correlated with fat mass (FM) (r = 0.74), waist size (r = 0.65), waist/height ratio (r = 0.64), and total skin fold (r = 0.77). Linear regression showed an association between change in BW and physical activity level (PAL) (B = -8.554; P = 0.025) confirmed by the multiple linear regression. Linear regression also revealed an association between change in FM and MMSE (B = 0.654; P = 0.027). CONCLUSION: In early PD, weight gain was revealed over three years accompanied by an increase in FM and waist circumference. An inverse relation was revealed between change in BW and PAL. The MMSE, UPDRS III, and Hoehn and Yahr rating were unchanged. Medication and swallowing difficulties were not associated with change in BW.
Authors: Philipp Homan; Miklos Argyelan; Christina L Fales; Anita D Barber; Pamela DeRosse; Philip R Szeszko; Delbert G Robinson; Todd Lencz; Anil K Malhotra Journal: Neuropsychopharmacology Date: 2019-07-17 Impact factor: 7.853
Authors: Luís César de Medeiros; Marcella Campos Lima da Luz; Jarson Pedro da Costa Pereira; Gleyce Kelly Araújo Bezerra; Poliana Coelho Cabral Journal: Neurol Sci Date: 2021-10-22 Impact factor: 3.307
Authors: Jacek Wilczyński; Agnieszka Pedrycz; Dariusz Mucha; Tadeusz Ambroży; Dawid Mucha Journal: Biomed Res Int Date: 2017-06-27 Impact factor: 3.411
Authors: Jun Kyu Mun; Jinyoung Youn; Jin Whan Cho; Eung-Seok Oh; Ji Sun Kim; Suyeon Park; Wooyoung Jang; Jin Se Park; Seong-Beom Koh; Jae Hyeok Lee; Hee Kyung Park; Han-Joon Kim; Beom S Jeon; Hae-Won Shin; Sun-Ah Choi; Sang Jin Kim; Seong-Min Choi; Ji-Yun Park; Ji Young Kim; Sun Ju Chung; Chong Sik Lee; Tae-Beom Ahn; Won Chan Kim; Hyun Sook Kim; Sang Myung Cheon; Jae Woo Kim; Hee-Tae Kim; Jee-Young Lee; Ji Sun Kim; Eun-Joo Kim; Jong-Min Kim; Kwang Soo Lee; Joong-Seok Kim; Min-Jeong Kim; Jong Sam Baik; Ki-Jong Park; Hee Jin Kim; Mee Young Park; Ji Hoon Kang; Sook Kun Song; Yong Duk Kim; Ji Young Yun; Ho-Won Lee; In-Uk Song; Young H Sohn; Phil Hyu Lee; Jeong-Ho Park; Hyung Geun Oh; Kun Woo Park; Do-Young Kwon Journal: PLoS One Date: 2016-09-13 Impact factor: 3.240